Objective To observe the therapeutic effects of atorvastatin on blood pressure and pregnancy associated plasma protein A ( PAPP - A ) in patients with prehypertension and hyperlipidemia. Methods Eighty patients with prehyperten-sion and hyperlipidemia were enrolled in the study and randomly divided into the treatment group and the control group. The control group was treated with placebo and the treatment group was treated with atorvastatin for 12 weeks. Blood pressure, pregnancy associated plasma protein A and lipid levels were checked after treatment and compared between the two groups. Results After 12 weeks of treatment, blood pressure, total cholesterol level ( TC ), triglyceride (TG), low density lipoprotein cholesterol level ( LDL - C ) and pregnancy associated plasma protein A ( PAPP - A ) were significantly decreased ( P < 0. 05 ), while high density lipoprotein cholesterol level ( HDL - C ) were significantly increased in the treatment group in comparison with the same group before treatment and with the control group ( P < 0. 05 ). No significant difference in the levels of blood pressure, pregnancy associated plasma protein A and lipid levels between before and after treatment was noted in control group ( P > 0. 05 ). Conclusion Intervention treatment with atorvastatin is one of the effective measures that decrease blood pressure and pregnancy associated plasma protein A in patients with prehypertension.%目的 探讨阿托伐他汀对高血压前期合并高脂血症患者血压及妊娠相关血浆蛋白A(PAPP-A)的影响.方法 将体检发现的80例高血压前期合并高脂血症患者随机分为治疗组和对照组,治疗组进行12周阿托伐他汀药物干预性治疗;对照组给予安慰剂治疗.观察两组患者治疗前后血压、血脂及PAPP-A水平的变化.结果 治疗12周后,治疗组血压、血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)及PAPP-A水平较治疗前及对照组均有明显下降(P＜0.05),血清高密度脂蛋白胆固醇(HDL-C)较治疗前及对照组明显上升(P＜0.05),而对照组治疗前后上述指标均无明显变化(P＞0.05).结论 阿托伐他汀在有效降脂的同时,可以降低高血压前期患者的血压及PAPP-A水平.
展开▼
